荣昌生物制药（烟台）股份有限公司

Home
About Us
RemeGen Co., Ltd. (Yantai) was co-founded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, and Dr. Jianmin Fang a Canadian-American scientist. RemeGen is headquartered in Yantai, Shandong Province, China, with R&D centers and offices in China and the United States.

■Our Company ■Our Vision ■Board of Directors ■Management Team
Products/R&D Pipelines
Telitacicept

The World’s First Innovative Dual-Target Biological Medication to Treat Systemic Lupus Erythematosus

Disitamab Vedotin

The First Independently Developed Novel ADC Drug in China

■Marketed Products ■Marketing Team ■Product Pipeline
Science&Manufacturing
■Innovation Capacity ■Technology Platform ■Manufacturing ■Quality System ■Talent Team
Investors

STAR Market stock code：荣昌生物：688331.SH

【2024.05.07】 Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024

HKEX stock code 荣昌生物：09995.HK

【2024.04.26】 [Overseas Regulatory Announcement - Other] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

■Financial Reports ■Circulars ■Activities and Presentations

■Investor Events Calendar ■Corporate Governance ■Investor Relation Contact Information
News
- Company News
- Media Reports
2026 EAU | Original Research Findings on Disitamab Vedotin Unveiled: Showcasing Breakthroughs in Urothelial Carcinoma Care

The Annual European Association of Urology Congress 2026 (EAU Congress 2026), one of the world’s premier urological events, was held in London, the United Kingdom, from March 13 to 16, 2026 (UTC+0). At the congress, results of multiple researches

■Company News ■Media Reports
Join Us
■Recruitment ■Working at RemeGen ■Compensation and Benefits
Contact Us
■Yantai, China

Address: No. 58 Beijing Middle Road, Yantai Development Zone, Shandong, China.

Telephone:（+86）535-3573511

■Company Address ■Clinical Trial ■Human Resource ■ Adverse Reactions Reporting

About Us

Home > About Us > Board of Directors > Xiaodi Su

Xiaodi Su

Non-Executive Director

Dr. Su Xiaodi has served as a non-executive director of the company since May 2020, primarily responsible for supervising the management matters of the board of directors.

Dr. Su Xiaodi obtained her bachelor's degree in Biological Sciences from Fudan University in Shanghai in 2008, and she obtained her Ph.D. in Immunology and Microbial Pathogenesis from Weill Medical College of Cornell University in the United States in 2014. From 2014 to 2015, she conducted postdoctoral research at the Special Surgery Hospital in New York, USA. She has approximately six years of experience in management consulting and investing in the biopharmaceutical industry.